Research programme: muscular dystrophies therapeutics - Pliant Therapeutics
Alternative Names: Anti-integrin mAbLatest Information Update: 28 Jul 2024
At a glance
- Originator Pliant Therapeutics
- Class Monoclonal antibodies
- Mechanism of Action Integrin stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Muscular dystrophies
Most Recent Events
- 28 Jul 2024 No recent reports of development identified for preclinical development in Muscular-dystrophies in USA
- 28 Feb 2022 Pliant Therapeutics plans to file IND application for muscular dystrophy in the US by the end of 2022
- 09 Nov 2021 Pilant Therapeutics plans to file IND application for Muscular dystrophy